Supplemental Digital Content 1

Inclusion criteria
Participants could be included in the study if:

• Participants’ parent(s)/legally acceptable representative(s), could and would comply, with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).

• They were a male or female between, and including, 84 and 95 months of age at the time of the booster vaccination.

• Written informed consent was obtained from the parent(s)/legally acceptable representative(s) of the participants and written informed assent was obtained from the participants in accordance with local laws and regulations.

• They were healthy participants as established by medical history and history-directed physical examination before entering into the study.

• They completed the vaccination in the primary study (NCT00326118) as per protocol.

Exclusion criteria:
Participants were excluded if they:

• Were a child in care (a child who has been placed under the control or protection of an agency, organisation, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation).

• Used any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the dose of study vaccine, or planned use during the study period.

• Were administered more than 14 days of immunosuppressants or other immune-modifying drugs within 6 months prior to the vaccine dose (for corticosteroids, prednisone ≥0.5 mg/kg/day, or equivalent). Inhaled and topical steroids were allowed.

• Were administered a vaccine not foreseen by the study protocol within the period starting 30 days before and ending 30 days after the study vaccine dose, with the exception of a licensed inactivated influenza vaccine which could be administered at any time during the study according to the local recommendations.

• Were concurrently participating in another clinical study, at any time during the study period, in which the participant had been or was exposed to an investigational or a non-
investigational vaccine/product (pharmaceutical product or device).

- Were previously vaccinated with meningococcal vaccine except the meningococcal vaccination received in the primary study.
- Had a history of meningococcal disease.
- Had any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including Human Immunodeficiency Virus infection, based on medical history and physical examination (no laboratory testing was required).
- Had a family history of congenital or hereditary immunodeficiency.
- Had a history of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine, and history of serious allergic reaction (anaphylaxis) following the administration of vaccine(s).
- Had major congenital defects or serious chronic illness.
- Had a history of any neurological disorders or seizures, including Guillain-Barré syndrome. History of a simple, single febrile seizure was permitted.
- Had acute disease and/or fever at the time of enrolment (fever was defined as temperature ≥37.5°C for oral, axillary or tympanic route, or ≥38.0°C for rectal route). Participants with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever could be enrolled at the discretion of the investigator.
- Were administered immunoglobulins and/or any blood products within the 3 months preceding the study vaccination or were planned administration during the vaccination phase of the study (Month 72–Month 73) and within 3 months preceding the blood sampling at 2 years after vaccination.

The following criteria were checked for the persistence phase at 2 years after vaccination:

- Previous administration of a meningococcal vaccine with the exception of the meningococcal vaccination given in the primary study and the meningococcal vaccination in this study.
- History of meningococcal disease.